<DOC>
	<DOCNO>NCT02323516</DOCNO>
	<brief_summary>The mechanisms action side effect associate targeted therapy still poorly understood . He find patient treated gefitinib , increased level thromboxane B2 P-selectin Thromboxane B2 result hydrolysis thromboxane A2 , obtain Prostaglandin H2 action thromboxane synthetase . The thromboxane A2 produce platelet active pro-thrombotic property follow : stimulation platelet activation increase platelet aggregation . The selectins cell adhesion protein role adhesion phenomenon . P-selectin express platelet endothelial cell . The demonstration increase plasma level thromboxane B2 P-selectin leave suggest role platelet activation occurrence side effect associate targeted therapy . Kanazawa 's study conduct 39 Japanese patient , try assess value low-dose acetylsalicylic acid 100mg per day , say , anti-aggr√©gantes dos , occurrence rash diarrhea induce gefitinib . In study , group patient treat acetylsalicylic acid present low rate side effect significantly , 58.3 % versus 77.8 % . The frequency diarrhea 18.5 % ( 5 patient ) standard group versus 0 % group acetylsalicylic acid . Similarly , find reduction occurrence skin rash , 33.3 % 4 patient acetylsalicylic acid group versus 74.1 % , 20 patient standard group . Finally , study , reveal significant difference term response treatment gefitinib ( 37 % standard group versus 33 % group treat aspirin patient ) It exist knowledge prospective data evaluate effect acetylsalicylic acid reduction side effect associate targeted population patient Caucasian-type treatment .</brief_summary>
	<brief_title>Evaluation Efficacy Low-dose Acetylsalicylic Acid Diarrhea Induced Anti-cancer Targeted Therapies .</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Loperamide</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<criteria>Aged least 18 year old patient ; WHO 0 2 ; Any solid tumor hematologic malignancy require tyrosine kinase inhibitor prescription absence digestive disorder related tumor disease ; Treatment one follow target therapy : Gefitinib , erlotinib , sunitinib , sorafenib , Axitinib , Pazopanib , Lapatinib , Imatinib , afatinib , vemurafenib Dabrafenib ; Targeted therapy treatment whatever processing line monotherapy , administered period least 15 day continue dose , usual care recommendation ; Diarrhea grade 13 accord NCI criterion CTCAE.4 , absence complication sign least 2 dos loperamide per day . Processing acetylsalicylic acid ; Allergy againstindications acetylsalicylic acid ( include concomitant antiplatelet anticoagulant consider increase risk bleed investigator ) acid ; Treatment anti vitamin K new oral anticoagulant ; Absolute pursuit target therapy contraindication ; Chronic diarrhea prior clinical introduction target therapy ; Diarrhoea unrelated targeted therapy : extend resection esophagus , inflammatory bowel disease , etc ... carcinoid syndrome ; occlusive syndrome ; Grade 3 diarrhea sign complication grade 4 Patients history grade 3 diarrhea sign complication grade 4 previous treatment TKI ; Participation medical test ; Pregnant woman / nursing ; Association methotrexate dos &gt; 15 mg / ; Patient Trust deprive liberty .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>